APA (7th ed.) Citation

W, W., X, N., S, L., B, C., L, C., C, Y., . . . S, L. (2026). Efavirenz Mitigates Dyslipidemia and Attenuates Ulcerative Colitis through Gut Microbiota Modulation. ACS infectious diseases, 12(6), 2136. https://doi.org/10.1021/acsinfecdis.6c00330

Chicago Style (17th ed.) Citation

W, Wang, et al. "Efavirenz Mitigates Dyslipidemia and Attenuates Ulcerative Colitis Through Gut Microbiota Modulation." ACS Infectious Diseases 12, no. 6 (2026): 2136. https://doi.org/10.1021/acsinfecdis.6c00330.

MLA (9th ed.) Citation

W, Wang, et al. "Efavirenz Mitigates Dyslipidemia and Attenuates Ulcerative Colitis Through Gut Microbiota Modulation." ACS Infectious Diseases, vol. 12, no. 6, 2026, p. 2136, https://doi.org/10.1021/acsinfecdis.6c00330.